Huons said it has signed a technology transfer agreement with EFIL BioScience for a functional material derived from the root vegetable parsnip, which is known for its potential benefits in supporting respiratory wellness.

EFIL BioScience, established in 2021, is a Korean biotech startup focusing on developing treatments for severe obesity, including therapies that regulate cholesterol metabolism and address appetite control disorders.

The decision to enter into the technology transfer agreement was driven by the significant potential for application and the high technical value of the parsnip extract technology, which EFIL BioScience has successfully patented in the U.S. Recognizing the extract's potential benefits for respiratory health, Huons aims to leverage this technology to develop innovative health functional foods.

Research conducted using parsnip extract on animals has demonstrated that the intake of processed parsnip extract can effectively reduce inflammation triggered by particulate matter and aid in repairing damage to the bronchial walls.

Given its origin from a widely consumed food source, Huons expects that the processed parsnip extract, as a functional food product, will contribute positively to respiratory health.

A Huons representative highlighted the current lack of individually recognized ingredients for respiratory health and expressed the company's commitment to pioneering the market for respiratory health functional materials.

"As there are no individually recognized ingredients for respiratory health to date, and with health authorities encouraging the development of such materials, we are dedicated to creating a market for respiratory health functional materials," a Huons official said.